G
Georgia Kollia
Researcher at Bristol-Myers Squibb
Publications - 63
Citations - 15738
Georgia Kollia is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Nivolumab & Pharmacokinetics. The author has an hindex of 24, co-authored 59 publications receiving 13985 citations.
Papers
More filters
Journal ArticleDOI
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian,F. Stephen Hodi,Julie R. Brahmer,Scott N. Gettinger,David Smith,David F. McDermott,John D. Powderly,Richard D. Carvajal,Jeffrey A. Sosman,Michael B. Atkins,Philip D. Leming,David R. Spigel,Scott J. Antonia,Leora Horn,Charles G. Drake,Drew M. Pardoll,Lieping Chen,William H. Sharfman,Robert A. Anders,Janis M. Taube,Tracee L. McMiller,Haiying Xu,Alan J. Korman,Maria Jure-Kunkel,Shruti Agrawal,Dan McDonald,Georgia Kollia,Ashok Kumar Gupta,Jon M. Wigginton,Mario Sznol +29 more
TL;DR: Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use.
Journal ArticleDOI
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian,Mario Sznol,David F. McDermott,Harriet M. Kluger,Richard D. Carvajal,William H. Sharfman,Julie R. Brahmer,Donald P. Lawrence,Michael B. Atkins,John D. Powderly,Philip D. Leming,Evan J. Lipson,Igor Puzanov,David Smith,Janis M. Taube,Jon M. Wigginton,Georgia Kollia,Ashok Kumar Gupta,Drew M. Pardoll,Jeffrey A. Sosman,F. Stephen Hodi +20 more
TL;DR: Overall survival following nivolumab treatment in patients with advanced treatment-refractory melanoma compares favorably with that in literature studies of similar patient populations, and responses were durable and persisted after drug discontinuation.
Journal ArticleDOI
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
Scott N. Gettinger,Leora Horn,Leena Gandhi,David R. Spigel,Scott J. Antonia,Naiyer A. Rizvi,John D. Powderly,Rebecca S. Heist,Richard D. Carvajal,David M. Jackman,Lecia V. Sequist,David Smith,Philip D. Leming,David P. Carbone,Mary Pinder-Schenck,Suzanne L. Topalian,F. Stephen Hodi,Jeffrey A. Sosman,Mario Sznol,David F. McDermott,Drew M. Pardoll,Vindira Sankar,Christoph Matthias Ahlers,Mark E. Salvati,Jon M. Wigginton,Matthew D. Hellmann,Georgia Kollia,Ashok Kumar Gupta,Julie R. Brahmer +28 more
TL;DR: Nivolumab monotherapy produced durable responses and encouraging survival rates in patients with heavily pretreated NSCLC, and overall survival, response durability, and long-term safety were reported.
Journal ArticleDOI
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
David F. McDermott,Charles G. Drake,Mario Sznol,Toni K. Choueiri,John D. Powderly,David Smith,Julie R. Brahmer,Richard D. Carvajal,Hans J. Hammers,I. Puzanov,F. Stephen Hodi,Harriet M. Kluger,Suzanne L. Topalian,Drew M. Pardoll,Jon M. Wigginton,Georgia Kollia,Ashok Kumar Gupta,Dan McDonald,Vindira Sankar,Jeffrey A. Sosman,Michael B. Atkins +20 more
TL;DR: Patients with advanced treatment-refractory RCC treated with nivolumab demonstrated durable responses that in some responders persisted after drug discontinuation, overall survival is encouraging, and toxicities were generally manageable.
Journal ArticleDOI
Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).
Joseph F. Grosso,Christine Horak,David Inzunza,Diana M. Cardona,Jason S. Simon,Ashok Kumar Gupta,Vindira Sankar,Jong-Soon Park,Georgia Kollia,Janis M. Taube,Robert A. Anders,Maria Jure-Kunkel,Jim Novotny,Clive R. Taylor,Xiaoling Zhang,Therese Phillips,Pauline Simmons,John Cogswell +17 more
TL;DR: The immune checkpoint receptor programmed death-1 negatively regulates T-cell activation and nivolumab, a PD-1 receptor blocking antibody, demonstrated durabicity in a phase I study.